Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Biotechnology

Healthcare
$19.79 -3.08%

-$0.74 today

Market cap
$290.48M
Beta
1.38
P/E (TTM)
-15.6
EPS (TTM)
-$1.49
52W Low $7.78High $34.10

Volume 0.23M

Average 0.14M

Returns on capital

Greenwich LifeSciences, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-1081.2%

avg -188.4%

ROIC

154.8%

avg 31.4%

ROA

287.3%

avg -2283.5%

Analysis

ROA is currently the strongest return metric at 287.3% versus its period average of -2283.5%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Snehal S. Patel

Chief Executive Officer, Chief Financial Officer & DirectorUSD 1.1M62——

Eric Rothe

Founder & Independent DirectorUSD 65.64K5182.70K0.56%

Christine T. Fischette

Vice President of Business Development—75——

Frank Joseph Daugherty

Chief Medical Officer & Director—76209.78K1.43%

Jaye L. Thompson

Vice President Clinical & Regulatory Affairs—60——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Dec 24, 2024.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

11

$475,672.00

Sells

0

$0.00

Net Transaction Value

+$475,672.00

Net buying

Most Active

Patel Snehal

11 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 29, 26

Patel Snehal

Direct

Buy$9.2K
Jul 28, 26

Patel Snehal

Direct

Buy$20.4K
Jul 27, 26

Patel Snehal

Direct

Buy$20.4K
Jul 24, 26

Patel Snehal

Direct

Buy$14.2K
Jul 23, 26

Patel Snehal

Direct

Buy$32.9K
Jan 13, 26

Patel Snehal

Direct

Buy$53.7K
Jan 12, 26

Patel Snehal

Direct

Buy$79.9K
Dec 31, 25

Patel Snehal

Direct

Buy$91.8K
Dec 30, 25

Patel Snehal

Direct

Buy$63K
Dec 18, 25

Patel Snehal

Direct

Buy$51.7K

1–10 of 11

Summary

Insiders reported 11 buys worth $475,672.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $475,672.00. Patel Snehal was the most active insider with 11 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Greenwich LifeSciences, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about GLSI's management, answered from reported figures.

Who manages GLSI?

Greenwich LifeSciences, Inc. (GLSI) lists 5 active executives. The top listed executive is Christine T. Fischette, Vice President of Business Development.

Are GLSI insiders buying or selling?

Recent insider activity shows net buying of $29.05M.